[关键词]
[摘要]
目的:探究奥洛他定治疗过敏性结膜炎的疗效及治疗前后患者血清及泪液中ECP及IgE水平的变化。方法:选取94例过敏性结膜炎患者并将其随机分为对照组及治疗组,各47例。对照组给予色甘酸钠滴眼液治疗,治疗组给予奥洛他定滴眼液治疗。治疗后2周统计2组临床疗效,记录并对比2组治疗前后临床症状改善情况;检测并比较2组治疗前后血清及泪液中相关指标水平的变化。结果:与治疗前比较,治疗后1、2周2组血清及泪液中HA、ECP、IgE水平均明显降低(P<0.05),且治疗组下降幅度显著优于对照组(P<0.05)。结论:奥洛他定治疗过敏性结膜炎的临床疗效显著优于色甘酸钠滴眼液,其可更有效地降低血清及泪液中ECP及IgE水平,快速缓解患眼临床症状。
[Key word]
[Abstract]
Objective: To explore the efficacy of olopatadine in the treatment of allergic conjunctivitis and the changes of ECP and IgE levels in the serum and tear before and after treatment. Methods:A total of 94 patients with allergic conjunctivitis were included in the study and randomized into the treatment group and the control group with 47 cases in each group. The patients in the control group were given sodium cromoglycate eye drops, while the patients in the treatment group were given olopatadine eye drops. After 2-week treatment, the clinical efficacy in the two groups was evaluated. The improvement of symptoms before and after treatment in the two groups was recorded and compared. The levels of serm and tear related indicators in the two groups were detected and compared. Results: When compared with before treatment, HA, ECP, and IgE levels in the serum and tear 1 and 2 weeks after treatment in the two groups were significantly reduced (P<0.05), and the reduced degree in the treatment group was significantly superior to that in the control group (P<0.05). Conclusions:Olopatadine in the treatment of allergic conjunctivitis can effectively reduce the serum and tear ECP and IgE levels, and rapidly alleviate the clinical symptoms of affected eye, with the clinical efficacy significantly superior to that by sodium cromoglycate eye drops.
[中图分类号]
R777.31
[基金项目]
湖北省科学技术厅(EK2016D170048001260)